ABSTRACT
PurposeThe COVID-19 pandemic has resulted in significant changes in consumer behaviour, which has had a cascading effect on consumer-centric logistics. As a result, this study conducts a focused literature review of pandemic-related consumer behaviour research to address two research questions: 1) what are the pandemic's direct effects on consumer consumption behaviour, with an emphasis on changes in their basic and psychological needs? and 2) what are the consequences of behavioural changes on consumer-centric logistics?Design/methodology/approachThe scientific procedure and rationales for systematic literature review (SPAR-4-SLR) protocol and the theory, context, characteristics and methodology (TCCM) framework were adopted as a guideline to map, refine, evaluate and synthesise the literature. A total of 53 research articles were identified for further analysis.FindingsUsing Maslow's hierarchy of human needs as a theoretical guide, this review synthesises the COVID-19 pandemic's effects on consumer behaviour into four categories: abnormal buying behaviour, changes in consumer preferences, digitalisation of shopping behaviour and technology-related behaviour. Furthermore, four consumer-centric logistics propositions are proposed based on the four aspects of consumer behavioural changes.Originality/valueThis study outlines the significant behavioural changes in consumers in the face of the COVID-19 pandemic and how these changes impact consumer-centric logistics, with implications for managing consumers' involvement in logistics and pointing out future research directions.
ABSTRACT
Objective: To explore the clinical practice of delivering radiotherapy during the outbreak of 2019 novel coronavirus disease(COVID-19). Method(s): During this epidemic period, available method including but not limited to: strict disinfection, body temperature monitoring and staff training of relevant knowledge, were used to ensure the safety of radiotherapy treatment. Statistical analysis was performed to study the relevant data including proportion of patients receiving radiotherapy for different purposes, time from scanning to the first time of radiation delivery and degree of satisfaction in the view of staffs and patients, respectively. Result(s): A total of 60 patients received radiation therapy in the department of radiotherapy of Zhejiang Provincial People's Hospital (2020-02-11). Compared with the same period in 2019 (after the Spring Festival), the total number of patients receiving radiotherapy was decreased from 72 to 60(83.3%). Among them, the number of patients receiving palliative radiation therapy decreased significantly, while the proportion of radical, preoperative and/or postoperative radiotherapy/radiochemotherapy did not significantly decrease. There was significant difference between two years (chi2=6.967, P<0.05). The median time for newly admitted patients to receive radiotherapy was two days, which was not significantly longer than the interval in 2019 (P>0.05). Staff and patients were generally satisfied with the current prevention measures. Conclusion(s): Using a variety of prevention and control method, and taking full account of medical safety and patient benefits, radiation-related activities can be carried out during the epidemic.Copyright © 2020 by the Chinese Medical Association.
ABSTRACT
The global COVID-19 outbreak has led to significant challenges for supply chain management, while insights on how to configure the supply chain network to respond to this crisis are limited. Therefore, the present research extends the understanding of supply chain resilience by investigating whether supply chain concentration has influenced the shock of COVID-19 on firm performance. This study assesses four sub-dimensions of supply chain concentration: supplier, customer, product, and region. Based on a large-scale sample of Chinese listed manufacturing firms, we employed a difference-in-difference approach to investigate whether supply chain concentration ameliorated or exacerbated the shock of COVID-19. The results indicate that treatment groups (firms with lower supplier, customer, product, and region concentration) have experienced a considerably more significant performance deterioration than control firms. Overall, this study paves the way for future research and offers vital insights into the redesign of supply chains in response to COVID-19 and similar crises. © 2023 Informa UK Limited, trading as Taylor & Francis Group.
ABSTRACT
Plasmonic metasurface biosensing has shown great potential in label-free detection of bio-nanoparticles with various sizes, such as cancer antigens, exosomes and SARS-CoV-2 virus. It typically relies on the immunoassay, but current studies usually neglect the perfect size matching between each target bio-nanoparticle and the surface near-field domain, which should be very critical for the enhancement of detection performance. In order to maximize the immunodetection capability for each bio-nanoparticle, we propose a plasmonic meta-biosensor based on the field-customized mechanism. Our design overcomes the serious interference of biofunctionalization and accomplishes a sensitivity of 27 times higher than the conventional nanoplasmonic counterpart. Our method also builds the important basis of single bio-nanoparticle immunodetection by a plasmonic metasurface. The customized plasmonic metasensing study implies a promising way towards ultra-low concentration biosensing or even single bio-nanoparticle detection for high-performance point-of-care-testing in the near future. © 1995-2012 IEEE.
ABSTRACT
Introduction: Infections by viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could cause viral myocarditis. Innate immunity to viral nucleic acids mediates antiviral immunity as well as inflammatory organ injury. However, the innate immune mechanisms that control the pathogenesis of viral myocarditis are unclear. Method(s): To understand the role of the E3 ligase Midline1 in controlling viral myocarditis, wild-type and Midline1 knockout mice were infected with coxsackievirus B3 (CVB3) or encephalomyocarditis (EMCV) for inducing viral myocarditis. Mice survivals and heart functions were monitored by transthoracic echocardiography, and hearts were harvested for histology analysis. Real-time PCR, western blotting, co-immunoprecipitation, enzyme-linked immunoassay, luciferase assay, flow cytometry, over-expression and knockdown techniques were used to understand the molecular mechanisms of Midline1 in regulating type I interferon production after virus infection in this study. Result(s): We find that Midline1 is induced by RNA viruses with heart tropisms CVB3 and EMCV. Knockdown or deletion of Midline1 in human or mouse macrophages enhances production of type I interferon (IFN) in response to double strand (ds) RNA, RNA viruses CVB3 or EMCV. Importantly, deletion of Midline1 protects mice from viral myocarditis induced by CVB3 or EMCV due to enhanced type I IFN production in vivo. Mechanistically, we show that Midline1 recruits protein phosphatase 1A (PPM1A) to dephosphorylate TANK binding kinase 1 (TBK1), which inactivates TBK1 to block TBK1 from interacting with its upstream adaptor mitochondrial antiviral signaling (MAVS), thereby dampening antiviral signaling during viral infections. Moreover, Midline1 stabilizes PPM1A by inducing K63-linked ubiquitination of PPM1A. Conclusion(s): Our results indicate that Midline1 serves as a negative regulator of viral myocarditis by downregulating innate immune activation induced by RNA viruses CVB3 and EMCV. Our data reveal that Midline1 is a critical regulator of innate immunity in viral myocarditis, thereby identifying a potential therapeutic target for treating viral induced cardiovascular diseases.
ABSTRACT
Objective: Studies have shown that COVID-19 affects intrapartum management, resulting in higher rates of cesarean delivery. However, it is unknown if COVID-19 infection increases rates of medically indicated deliveries. The primary objective was to determine if there are differences in medical indications for delivery in COVID-19 positive patients. Study design: This is a prospective cohort study of patients admitted for delivery at an urban obstetrical unit from April-November 2020 where patients were tested for COVID-19 following admission. Baseline demographics, labor and delivery information, and outcomes were recorded, and composite maternal and neonatal outcomes were compared between COVID-19 positive and negative patients using Fisher's exact tests and a Poisson regression analysis to adjust for confounders. Result(s): 545 deliveries were included, with 56 (10.33%) COVID-19 positive and 486 (89.67%) negative patients. There were no differences in rate of medical indications for delivery. There was a higher rate of cesarean delivery in the COVID-19 positive group (46.43% versus 31.28%, p=.034), although there was no difference in indications for cesarean delivery. Additionally, for COVID-19 positive patients, there were higher rates of preterm births (p=.014) but no increase in preterm labor. There was an increase in composite adverse neonatal outcomes (p= <0.05), but not composite adverse maternal outcomes. Conclusion(s): Despite an increase in cesarean delivery, there was no difference in medical indications for delivery in COVID-19 patients. Although there was an increase in composite adverse neonatal outcomes, this may be attributed to an increase in admission of exposed newborns to the neonatal intensive care unit. Disclosure: No [Formula presented] Copyright © 2022
ABSTRACT
Background: Patients on warfarin require regular international normalized ratio (INR) monitoring. The SARS-CoV- 2 pandemic may have substantially affected in-person medical visits and laboratory testing. However, it is not clear how warfarin monitoring practices have been affected by the pandemic, given the importance of tight INR control. Aim(s): To assess whether chronic warfarin management, as measured by INR testing frequency and time in therapeutic range (TTR), differed during the COVID-19 pandemic compared with the pre-pandemic period. Method(s): We identified all patients enrolled in an anticoagulation clinic associated with an urban academic medical between January 1, 2019 and May 31, 2021 with at least 2 INRs checked during this time period. We calculated frequency of INRs checked per month and TTR based on individual INR goals and compared the pre-pandemic (Jan 2019-Feb 2020) and pandemic (March 2020-May 2021) periods. INR frequency and TTR were modeled as a function of time period using Poisson and linear regressions respectively, accounting for repeated observations. Result(s): Of the 1052 patients included, 43.9% were women and average age was 66.3 years. Pre-pandemic, an average of 1.58 (95% CI 1.52-1.64) INRs were checked per month, as compared with 1.09 (95% CI 1.03-1.15) in the pandemic period (p< 0.001) (Figure 1). Average TTR per month was also calculated (Figure 2). On average, TTR was 56.8% (95% CI 54.9-58.8%) pre-pandemic compared to 39.4% (95% CI 37.5-41.5%) during the pandemic period (p < 0.001). (Table Presented) Conclusion(s): There was a significant decrease in the frequency of INR measurements as well as TTR during the pandemic. A number of factors may have contributed to this, including regulatory and logistical constraints on clinic and laboratory visits and patient anxiety about visiting medical facilities. Larger scale studies are warranted to further characterize pandemic effects on warfarin use and monitoring, as well as clinically significant outcomes of thrombosis and hemorrhage.
ABSTRACT
Background. The data on CAPA in the U.S. are limited to date and clinical characteristics unique to this phenomenon have not been widely reported. Methods. This retrospective observational study was conducted at multiple VA hospitals across southern California and Arizona. CAPA cases were identified in inpatients with laboratory-confirmed COVID-19 based on microbiologic or serologic evidence of aspergillosis and pulmonary abnormalities on imaging, and were classified according to ECMM/ISHAM consensus definitions. Characteristics of interest included immunosuppressive/modulatory agents used prior to onset of CAPA, COVID-19 disease course, length of hospitalization, and mortality. Results. Seventeen patients with probable (18%) or possible (82%) CAPA were identified from April 2020 to March 2021. Values below reported as medians. All patients were male and 13 (76%) were white, with age 74 years and BMI 26 kg/m2. Baseline comorbidities included diabetes mellitus (47%), cardiovascular disease (65%), and pulmonary disease (71%). Evidence of aspergillosis was mostly based on respiratory culture, with mainly A. fumigatus (75%). Systemic corticosteroids were used in 14 patients, with a total dose of 400 mg prednisone equivalents starting 10 days prior to Aspergillus detection. Patients also received tocilizumab (18%), leflunomide (6%), tacrolimus (6%), mycophenolate (6%), and investigational agent LSALT or placebo (6%);2 patients (12%) did not receive any immunosuppression/modulation. Length of hospitalization for COVID-19 was 22 days. Death occurred in 12 patients (71%), including all patients with probable CAPA, at 34 days after COVID-19 diagnosis and 16 days after CAPA diagnosis. Eight patients (47%) were treated for aspergillosis;mortality did not appear to differ with treatment (75% vs. 67%). Conclusion. This case series reports high mortality among patients with CAPA;the primary contributor to this outcome is unclear. Frequency of lower respiratory tract sampling in patients with COVID-19 may have limited diagnosis of CAPA. Interestingly, inpatient respiratory cultures with Aspergillus spp. increased compared to previous years. Future work will attempt to identify risk factors for CAPA and attributable mortality via comparison to inpatients with COVID-19 without CAPA.
ABSTRACT
Wearing a mask has proven to be one of the most effective ways to prevent the transmission of SARS-Co V-2 coronavirus. However, wearing a mask poses challenges for different face recognition tasks and raises concerns about the performance of masked face presentation detection (PAD). The main issues facing the mask face PAD are the wrongly classified bona fide masked faces and the wrongly classified partial attacks (covered by real masks). This work addresses these issues by proposing a method that considers partial attack labels to supervise the PAD model training, as well as regional weighted inference to further improve the PAD performance by varying the focus on different facial areas. Our proposed method is not directly linked to specific network architecture and thus can be directly incorporated into any common or custom-designed network. In our work, two neural networks (DeepPixBis [21] and MixFaceNet [4]) are selected as backbones. The experiments are demonstrated on the collaborative real mask attack (CRMA) database [17]. Our proposed method outperforms established PAD methods in the CRMA database by reducing the mentioned shortcomings when facing masked faces. Moreover, we present a detailed step-wise ablation study pointing out the individual and joint benefits of the proposed concepts on the overall PAD performance. © 2021 IEEE.
ABSTRACT
Introduction: Chinese patent medicine (CPM) is an indispensable part of traditional Chinese medicine. Coronavirus Disease 2019 (COVID-19) manifests is an acute respiratory infectious disease. This systematic review aimed to evaluate the therapeutic effects and safety of oral CPM for COVID-19. Methods: We included randomized controlled trials (RCTs) that tested oral CPM for the treatment of COVID-19 identified from publications in CNKI, Wanfang, VIP, Web of Science, SinoMed, PubMed, Embase, BioRxiv, MedRxiv and arXiv before November 2nd, 2020. The risk of bias for each trial was assessed using the Cochrane Risk of Bias Tool 2.0. RevMan 5.4 software was used for data analyses. The certainty of the evidence was assessed using the online GRADEpro tool. Results: Seven RCTs including 1079 participants were identified. The overall bias was assessed as “some concerns” for all included trials. Oral CPM investigated were: Lianhua Qingwen capsule/granules (连花清瘟胶囊/颗粒, LHQW), Jinhua Qinggan granules (金花清感颗粒, JHQG), Huoxiang Zhengqidripping pills (藿香正气滴丸, HXZQ), Toujie Quwen granules (透解祛瘟颗粒, TJQW) and Lianhua Qingke granules (连花清咳颗粒, LHQK). Compared with conventional western therapy alone for people with COVID-19: regarding the main outcomes, the results showed that oral CPM combined with conventional western therapy improved cure rate (RR = 1.20, 95% CI 1.04 to 1.38, involving LHQW and TJQW), reduced aggravation rate (RR = 0.50, 95% CI 0.29 to 0.85, involving LHQW, JHQG, LHQK and TJQW);with regard to additional outcomes, the results showed that add-on oral CPM shortened the duration of fever, cough and fatigue, improved the recovery rate of cough and fatigue, and increased the improvement and recovery rate of chest CT manifestations. There were some differences in therapeutic effects among various CPMs for the same COVID-19 outcome. The use of TJQW and LHQG appeared not to increase the risk of adverse events, but JHQG may cause mild diarrhea. Conclusions: Low-certainty or very low-certainty evidence demonstrated that oral CPM may have add-on potential therapeutic effects for patients with non-serious COVID-19. There are some differences in therapeutic effects between different oral CPMs for the same outcome of COVID-19. The use of TJQW and LHQG probably does not increase the risk of adverse events, but JHQG may cause mild diarrhea in patients. The conclusion of this review needs to be further confirmed by well-designed clinical trials with adequate sample sizes. Keywords: Coronavirus Disease 2019;COVID-19;Chinese patent medicine;Chinese herbal medicine;Systematic review;Meta-analysis
ABSTRACT
Introduction: Mechanistic research suggests that diabetes may increase susceptibility to infection. However, few epidemiologic studies have examined this association. Hypothesis: We hypothesize that adults with diabetes will have a higher risk for infection compared to those without diabetes. Methods: We conducted a prospective cohort analysis of diabetes and incident hospitalization with infection using data from the Atherosclerosis Risk in Communities (ARIC) Study. We used Cox regression models with adjustments for demographics, health behaviors, and cardiometabolic and kidney functioning measures. Diabetes status at baseline (1987-1989) was defined as a fasting glucose ≥126 mg/dL or non-fasting glucose ≥200 mg/dL, or self-report of a diagnosis of diabetes, or current diabetes medication use. First hospitalization with any infection and specific types of infections (respiratory, urinary, foot, sepsis, and postoperative wound) were ascertained from ICD-9 codes in hospital discharge records, with follow-up to September 30, 2015. Results: We included 13,356 participants (mean age, 55;26% black;54% female). During a median follow-up of 18.8 years, there were 7,791 incident hospitalizations with infection. Compared to those without diabetes at baseline, those with diabetes had a greater risk for hospitalization with any infection (adjusted HR: 1.55 [95% CI: 1.45-1.66], Table ). Results were generally consistentacross infection type, and differences were especially pronounced for foot infections (adjusted HR:6.35 [95% CI: 5.27-7.64]). Conclusion: The COVID-19 pandemic has heightened interest in the link between diabetes and susceptibility to infection. Our study suggests diabetes confers significant risk for infection.Enhancing diabetes prevention and management may reduce infection-related morbidity and mortality.